{
  "main_header": {
    "sid": 384463,
    "name": "Vista Pharma.",
    "stock_name": "Vista Pharma.",
    "full_name": "Vista Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/vista-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "7.46",
    "chg": -0.06,
    "chgp": "-0.8%",
    "dir": -1,
    "prev_price": "7.52",
    "mcapval": "46.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524711,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE427C01021",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "840 ",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswaluat.com/MOSL-Landingstocks-analysis/vista-pharma-384463-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 5697,
    "sid": "384463",
    "stock_news_url": "https://marketsmojo.motilaloswaluat.com/news/vista-pharmaceuticals-384463"
  },
  "announcements": [
    {
      "caption": "Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "29-May-2026",
      "details": "Board meeting outcome",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "29-May-2026",
      "details": "SEBI Secretarial Compliance Report for the year ended 31.03.2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2026",
      "datetime": "19-May-2026",
      "details": "Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.2026 2. Audit Report for the quarter and year ended 31.03.2026 3. Any other business with the permission of the Chair.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News